Mitigating the burden of SARS-CoV-2 in at-risk populations with adapted COVID-19 vaccines
The webinar will explore how the burden of SARS-CoV-2 variants may be mitigated with adapted vaccines. It will delve into the current burden of SARS-CoV-2 variants and populations at risk, data on adapted vaccine efficacy and safety, and vaccination strategies.
Learning objectives
- Appraise surveillance data on dominant circulating influenza and SARS-CoV-2 strains to inform optimal vaccine composition beyond the pandemic period
- Discuss immunological considerations for optimized vaccine design against prevalent influenza and COVID strains
- Evaluate vaccine effectiveness data against emergent RID strains and strategies to enhance broad protective immunity against antigenic variants
- Examine vaccine platforms (e.g. mRNA) for rapid adaptation against evolving epitopes of RID pathogens
For more information, view the full agenda.
Meet Your Expert Panel
- Luke Moore, Imperial College, Infectious Diseases, Microbiology, & Virology, London
- Martina Prelog, University of Wuerzburg, Pediatric Rheumatology and Special Immunology
- Albert Osterhaus, University of Veterinary Medicine Hannover, Germany
These renowned experts will explore the burden of SARS-CoV-2 variants in populations at risk and discuss mitigation strategies using adapted vaccines.
